Showing results (341-350 of 536) with videos related to

Sort By:
Pageof 54
Hypertension (Dallas, Tex. : 1979)|March 8, 2003
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathyChristos Tikellis, Colin I Johnston, Josephine M Forbes, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 6, 2003
The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetesJosephine M Forbes, Vicki Thallas, Merlin C Thomas, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 5, 2019
Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical OutcomesToshiaki Ohkuma, Min Jun, John Chalmers, et al.
Diabetes|October 29, 2002
ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 ratJennifer L Wilkinson-Berka, Darren J Kelly, Suzanne M Koerner, et al.
JACC. Advances|November 8, 2025
Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 DiabetesAnne T Reutens, Dulari Hakamuwa Lekamlage, Agus Salim, et al.
Diabetes Research and Clinical Practice|June 14, 2005
Diabetes induces Na/H exchange activity and hypertrophy of rat mesenteric but not basilar arteriesRodney J Dilley, Caroline A Farrelly, Terri J Allen, et al.
Journal of the American Society of Nephrology : JASN|December 31, 2004
Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout miceMarkus Lassila, Karin Jandeleit-Dahm, Kwee K Seah, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 10, 2019
Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trialVlado Perkovic, Audrey Koitka-Weber, Mark E Cooper, et al.
Journal of Hypertension|August 13, 2002
Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockadeFabrice Bonnet, Riccardo Candido, Robert M Carey, et al.
Pageof 54